Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)

NCT07297745 is registered in ClinicalTrials.gov with Changi General Hospital as lead sponsor.

NCT NCT07297745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07297745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
Lead sponsor
Changi General Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
January 15, 2026
Completion date
December 31, 2029
Enrollment
120 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hyperaldosteronism; primary, primary aldosteronism due to aldosterone producing adenoma